Despite good outcomes for patients with moderate arthritis [39,40], some adverse events increased following the application of COX-2 inhibitors in osteoarthritis patients, including abdominal pain, hypertension, heart failure, and edema [52]. This evidence concerns the gene PTGS2 and heart failure.